Top Markets
Coin of the day
GBS Inc. GBS Inc.

GBS Inc.

GBS
株式のランク #33713
Operating across North America and the Asia-Pacific region, GBS Inc.... Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
株価
$0.4732
最終同期: 2022-10-26
時価総額
$7.05M
変化(1日)
-0.03%
変化(1年)
0.00%
US
取引 GBS Inc. (GBS)

カテゴリー

GBS Inc.(GBS)の配当利回りの履歴
GBS Inc.(銘柄コード: GBS)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
GBS Inc.(GBS)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)